🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. SOF

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic HCV Infection

    phase 3 small molecule completed

    2 trials

  2. SP-102

    Semnur Pharmaceuticals

    Lumbosacral Radicular Pain

    phase 3 small molecule active

    3 trials

  3. SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM

    Ars Pharmaceuticals Irl Limited

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    1 trial

  4. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial

  5. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule terminated

    2 trials

  6. SPN-810 (18 mg)

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  7. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  8. SUZ

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 3 small molecule completed

    1 trial

  9. SYR-322-MET

    Takeda

    Clinical Pharmacology

    phase 3 small molecule completed

    1 trial

  10. Safinamide 100 mg PLACEBO: Safinamide 100 mg PLACEBO film-coated tablets have the same composition as the relevant Investigational Medicinal Products except for the presence of Active Substance that is missing in the placebo formulations. The missing amount of active substance Safinamide methanesulfonate is replaced in the PLACEBO formulation with the same amount of Microcrystalline cellulose, one of the excipients already present in the authorised formulation, Xadago 100 mg film-coated tablets, Xadago 50 m

    Verona Pharma Ireland Limited

    PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS

    phase 3 small molecule active

    1 trial

  11. Sapropterin Dihydrochloride

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonurias

    phase 3 small molecule completed

    3 trials

  12. Sapropterin dihydrochloride

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria

    phase 3 small molecule completed

    4 trials

  13. Sativex

    Jazz Pharmaceuticals Ireland Limited

    Pain

    phase 3 small molecule completed

    6 trials

  14. Sativex

    Jazz Pharmaceuticals Ireland Limited

    Cerebral Palsy

    phase 3 small molecule completed

    1 trial

  15. Sativex®

    Jazz Pharmaceuticals Ireland Limited

    Spasticity

    phase 3 small molecule completed

    3 trials

  16. Sativex®

    Jazz Pharmaceuticals Ireland Limited

    Detrusor Overactivity

    phase 3 small molecule completed

    1 trial

  17. Seasonale (levonorgestrel and ethinyl estradiol)

    Teva Pharma GmbH

    Osteopenia

    phase 3 small molecule terminated

    1 trial

  18. Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]

    Teva Pharma GmbH

    Healthy

    phase 3 small molecule completed

    1 trial

  19. Secukinumab

    Novartis Pharmaceuticals

    Psoriatic Arthritis

    phase 3 small molecule completed

    2 trials

  20. Secukinumab

    Novartis Pharmaceuticals

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  21. Secukinumab

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 small molecule completed

    1 trial

  22. Secukinumab (75 mg)

    Novartis Pharmaceuticals

    Psoriatic Arthritis

    phase 3 small molecule completed

    1 trial

  23. Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 small molecule completed

    1 trial

  24. Selatogrel

    Viatris Pharmaceuticals Co.,

    Acute Myocardial Infarction

    phase 3 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources